Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Raderer

Showing results (81-90 of 264) with videos related to

Pageof 27
Sort By:
Hematological Oncology|December 3, 2024
Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT-Lymphoma) of the Intestine: A Single Center AnalysisOskar Steinbrecher, Barbara Kiesewetter, Werner Dolak, et al.
Annals of Hematology|April 6, 2012
Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspectsBarbara Kiesewetter, Leonhard Müllauer, Berthold Streubel, et al.
The Journal of Clinical Endocrinology and Metabolism|July 2, 2010
High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxelMarlene Troch, Oskar Koperek, Christian Scheuba, et al.
Journal of Cancer Research and Clinical Oncology|February 19, 2025
Patterns and outcomes of current antitumor therapy for high-grade neuroendocrine neoplasms: perspective of a tertiary referral centerPhilipp Melhorn, Julia Spitzer, Thomas Adel, et al.
The Oncologist|December 2, 2015
Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue LymphomaBarbara Kiesewetter, Marlene Troch, Marius E Mayerhoefer, et al.
Haematologica|April 14, 2011
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphomaWolfgang Lamm, Hannes Kaufmann, Markus Raderer, et al.
Oncology|September 29, 2004
Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphomaBerthold Streubel, Hongtao Ye, Ming-Qing Du, et al.
Oncology|August 23, 2016
Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter?Barbara Kiesewetter, Julius Lukas, Werner Dolak, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|August 7, 2004
Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case reportStefan Wöhrer, Jutta Ackermann, Catrin Baldia, et al.
Cancers|December 1, 2020
First Line Systemic Treatment for MALT Lymphoma-Do We Still Need Chemotherapy? Real World Data from the Medical University ViennaBarbara Kiesewetter, Ingrid Simonitsch-Klupp, Marius E Mayerhoefer, et al.
Pageof 27

Showing results (81-90 of 264) with videos related to

Sort By:
Pageof 27
Hematological Oncology|December 3, 2024
Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT-Lymphoma) of the Intestine: A Single Center AnalysisOskar Steinbrecher, Barbara Kiesewetter, Werner Dolak, et al.
Annals of Hematology|April 6, 2012
Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspectsBarbara Kiesewetter, Leonhard Müllauer, Berthold Streubel, et al.
The Journal of Clinical Endocrinology and Metabolism|July 2, 2010
High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxelMarlene Troch, Oskar Koperek, Christian Scheuba, et al.
Journal of Cancer Research and Clinical Oncology|February 19, 2025
Patterns and outcomes of current antitumor therapy for high-grade neuroendocrine neoplasms: perspective of a tertiary referral centerPhilipp Melhorn, Julia Spitzer, Thomas Adel, et al.
The Oncologist|December 2, 2015
Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue LymphomaBarbara Kiesewetter, Marlene Troch, Marius E Mayerhoefer, et al.
Haematologica|April 14, 2011
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphomaWolfgang Lamm, Hannes Kaufmann, Markus Raderer, et al.
Oncology|September 29, 2004
Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphomaBerthold Streubel, Hongtao Ye, Ming-Qing Du, et al.
Oncology|August 23, 2016
Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter?Barbara Kiesewetter, Julius Lukas, Werner Dolak, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|August 7, 2004
Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case reportStefan Wöhrer, Jutta Ackermann, Catrin Baldia, et al.
Cancers|December 1, 2020
First Line Systemic Treatment for MALT Lymphoma-Do We Still Need Chemotherapy? Real World Data from the Medical University ViennaBarbara Kiesewetter, Ingrid Simonitsch-Klupp, Marius E Mayerhoefer, et al.
Pageof 27